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Transplant Outcomes
Median OS (years) 5.9548
Acute GVHD Grade:
0-2 15 (68.2)
3-5 7 (31.8)
Chronic GVHD:
None 10 (50)
Limited 4 (20)
Extensive 6 (30)
NRM at 1 year 7 (35%)
Median Survival (years)
per GVHD prophylaxis regimen:
Calcineurin inhibitor/MTX 14.4
Calcineurin inhibitor/MYC 2.3241
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Background: Allogeneic bone marrow transplantation (allo-
BMT) in Multiple Myeloma (MM) offers a potential curativeTable 1
Patient Characteristics (N ¼ 22)
N (%)
Median Age (years) 49.5
Sex:
Male 8 (36)
Myeloma Subtype:
Kappa light chain 2 (9.1)
Lambda light chain 3 (13.6)
IgA 3 (13.6)
IgG 13 (59.1)
Minimally secretory 1 (4.5)
DSS:
I 3 (13.6)
II 3 (13.6)
III 16 (72.7)
Response prior to transplant:
CR 2 (9.1)
PR1 4 (18.2)
PR2+ 8 (36.4)
SD/MR 5 (22.7)
PD 2 (9.1)
Unknown 1 (4.5)
Donor:
MUD 3 (13.6)
MRD 19 (86.3)
HLA-matching:
9/10 10 (45.5)
10/10 12 (54.5)
Conditioning regimen:
FLU/CY 1 (4.5)
FLU/MEL 8 (36.4)
FLU/MEL/ATG 2 (9.1)
MEL/TBI 9 (40.9)
TBI 2 (9.1)
Source of Stem Cells:
Peripheral Blood 8 (36.4)
Bone Marrow 14 (63.6)
GVHD prophylaxis:
CYA 1 (4.5)
CYA/MTX 8 (36.4)
CYA/MYC 2 (9.1)
TAC/MTX 2 (.1)
TAC/MYC 9 (40.9)strategy. This study was undertaken to determine outcomes
of patients with MM undergoing allogeneic BMT at Temple
University Hospital over the past 18 years.
Methods: We retrospectively reviewed our clinical database
for patients with a diagnosis of MM who underwent an allo-
BMT between 1994 to present. We reviewed the following
variables: Age, sex, myeloma subtype and stage, remission
status prior to transplant, stem cell source and degree of
donor matching, conditioning regimen, GVHD prophylaxis.
Outcome measures included overall survival, non-relapsed
mortality (NRM), and acute and chronic GVHD.
Results: Patient characteristics are summarized in the Table
1. The median age was 49.5 years, 72.7% had DSS III, 68% had
either at least PR2, PD or SD/MR, and 86.3% had a MRD
transplant. The outcomes are summarized in Table 2. The
median actuarial overall survival for the cohort is 5.95
years and the ten year actuarial survival for the cohort is
34%. Median survival with a Calcineurin inhibitor (CUI) and
methotrexate combination for GVHD prophylaxis was 14.4
years, as compared to 2.2 years for CUI and mycophenolate
based regimens (P ¼ .05). The relapse rate for the cohort
was 31.8%, Grade 3 or more acute GVHD developed in
31.8%, while extensive chronic GVHD occurred in 30% of
the patients.
Conclusion: Allogeneic transplantation is a reasonable
strategy in patients with MM which can lead to long-term
survival. Patients receiving GVHD prophylaxis with a CUI and
Methotrexate experienced superior survival compared to
those receiving a CUI and mycophenolate based regimen.
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Various preparative regimens are utilized for autologous
transplantation in patients with relapsed diffuse large cell
lymphoma, including TBI based regimens. The most
commonly used regimen includes Ara-C + Etoposide +
Melphalan + BCNU (BEAM). At our institution the ablative
regimen utilized includes Cytoxan 7200 mg/m2, BCNU
400mg/m2 and Etoposide 2400mg/m2 (Augmented CBV).
Abstracts / Biol Blood Marrow Transplant 19 (2013) S233eS256S234We performed a secondary analysis of North Shore
University Hospital's (NSUH) Center for International Blood
and Marrow Transplant Research (CIBMTR) data to describe
the relapse and survival of our diffuse large cell lymphoma
patients in second remission / response undergoing high
dose chemotherapy and autologous stem cell transplantation
from December 2007 to March 2012.
Our primary aimwas to evaluate overall and progression-
free survival at 100 days and 1 year post transplant.
Descriptive statistics (mean, standard deviation, frequencies
and proportions) were calculated for demographics and
clinical factors. The Kaplan-Meier product-limit method was
used to estimate OS and PFS. Subjects inwhich the outcomes
of interest (death or progression) were not observed were
considered censored using their last date of follow-up.
This analysis consisted of 29 patients; mean age 57.85
years. The 100-day and one year overall survival rates were
89.66% and 67.81%, respectively. The 100-day and one year
progression free survival rates were 78.57% and 73.33%,
respectively. Among those patients who died, the primary
causes of death were bacterial infection, recurrence of
primary disease, and cardiac failure.
These outcomes appear comparable to those provided by
the Center for International Blood and Marrow Transplant
Research. Thus allowing us to conclude that Augmented CBV
is a viable preparative regimen for patients with relapsed
diffuse large cell lymphoma undergoing autologous stem cell
transplantation.243
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Sarcopenia is a state of abnormally low muscle mass that
is associated with more treatment-related complications,
shorter time to recurrence or progression, and shorter overall
survival in patients with different cancers, including
lymphoma, pancreatic, lung, and breast cancer. Sarcopenia is
a potentially modiﬁable host factor that can be easily and
reliably obtained from routine computerized tomography
(CT). The objective of this study is to determine whether
sarcopenia impacts transplant-related outcomes in patients
undergoing autologous and allogeneic hematopoietic stem
cell transplantation (HSCT) for Hodgkin's lymphoma (HL) or
non-Hodgkin's lymphoma (NHL). Patients transplanted
between 6/2005 and 6/2012 at the University of Michigan
BMT Program were eligible for inclusion if a CT of the
abdomen was performed within 60 days prior to HSCT.
Cross-sectional area and density of the psoas muscles at the
level of the fourth lumbar vertebra were calculated. Lean
psoas muscle mass accounting for fatty inﬁltration was
determined using algorithms programmed in the Analytic
Morphomics Lab at the University of Michigan.
Results: Total psoas area and lean psoas area were calculated
for 121 autologous transplant patients who met inclusion
criteria. The median total psoas area/height was 1255.2
mm2/m and the median lean psoas area/height was 977.4
mm2/m. After controlling for age and gender, the hazard ratio
for non-relapse mortality (NRM)was 0.79 (C.I. 0.60,1.05), P¼.088 for every 100mm2/m increase in total psoas area/height
and 0.75 (C.I. 0.55, 1.04), P ¼ .099 for every 100 mm2/m
increase in lean psoas area/height. Patients were then
divided into tertiles for total psoas area/height and lean
psoas area/height. Since only one NRM event was observed
among included women and occurred in a woman in the
lowest tertile for total psoas area/height and lean psoas area/
height, the tertile anlaysis was conducted in only men.
Among all included men, a greater NRM was seen in the
patients in the bottom two tertiles, compared to the tertile
with the greatest muscle mass and can be observed in the
attached ﬁgure (P ¼ .02 and P ¼ .03 for a log-rank test of the
lowest and middle tertile respectively). In the 43 allogeneic
transplants, sarcopenia had no impact on outcome.
Conclusion: Patients with a greater degree of pre-transplant
sarcopenia who underwent an autologous HSCT for NHL or
HL had a greater risk of NRM than those with greater muscle
mass. CT-determined psoas muscle mass may be a valuable
addition to comorbidity indices used to guide optimal
treatment selection and serve as a potentially modiﬁable
host factor to improve transplant-related outcomes. This
difference was not noted in the allogeneic transplant pop-
ulation, where a different and more complex set of compli-
cations may come into play, although this requires
conﬁrmation in a larger sample.
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Background: Immunoglobulin light chain amyloidosis (AL)
is characterized by deposition of insoluble ﬁbrils composed
of immunoglobulin light chains, causing progressive organ
dysfunction. Renal involvement is seen in 50% of cases of AL,
which, if left untreated, progresses to end-stage renal disease
(ESRD).
Methods: We performed a retrospective analysis in 75
patients (pts) with AL with renal involvement who under-
went high-dose chemotherapy and autologous hematopoi-
etic stem cell transplantation (auto-HCT) at our institution
between 1999 and 2011. Fifty-ﬁve of these AL pts had
renal involvement, as deﬁned by the International
Consensus Criteria (Ref. Gertz M et al. AJH 2005). Primary
objectives were to assess hematologic and organ response,
